MAGE-A3 With Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine

Abstract

We have demonstrated for the first time, to our knowledge, that cloning and purification of MAGE-A3 with CPD enhances its cytosolic bioavailability in DCs without altering cell-surface antigens, potentially making it a more potent therapeutic cancer vaccine compared with existing MAGE-A3 protein and peptide vaccines.

MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A∗0201 alleles

“…6C). In our simulation the horse shoe like (C 2 H 4 O) 6 from PEG400 could be removed, but the conformation of whole structure was not affected. The structure is sufficient to test the other unknown peptides from MAGEA10.…”

“…Because both germ cells are devoid of surface HLA class I molecules, the responses of specific CD8 + cytotoxic T lymphocytes (CTL) to antigens encoded by MAGE genes have been suggested to be strictly tumor specific, but in different cancers, in other words they are cancer antigens [5][6][7][8]. MAGE molecules in cancer cells can be degraded by proteasome mediated proteolysis with cellular ubiquitin, and the degraded peptides can be transported to the cell surface by antigen processing protein.…”

MAGE-A3: an Immunogenic Target Used in Clinical Practice

“…In addition to adjuvant selection, novel strategies will improve the efficacy of immunotherapeutic approaches. For instance, incorporation of cell-penetrating domains to MAGE-A3 expressing vector has been shown to increase its cytosolic bioavailability in DCs without any change in cell-surface antigens [149].…”

Effective Delivery of Cancer Vaccines with Oxidatively Photo-Inactivated Transgenic Leishmania for Tumor Immunotherapy in Mouse Models

“…Of interest is to study the mechanism of adjuvanticity of photo-inactivated Leishmania in detail for comparison with other DAMP and PAMP adjuvants. Tumor antigens have been delivered to patients' DC via conjugation with cell-penetrating peptides [21] and adeno-associated virus vectors [22] for ex vivo vaccination to activate CD8+ T cells for CTL activities of anti-tumor immunity. Such protocols are being developed for use with inactivated hENO1-Leishmania toward DC-based immunotherapy of human lung cancer.…”